3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hematologic Neoplasms
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Liver Neoplasms
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
4
Nivolumab
4
Ipilimumab
2
Interleukin-2
2
Drug Therapy
2
Biopsy
2
poly ICLC
1
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
cobimetinib
1
cemiplimab
1
cc-486
1
brodalumab
1
atezolizumab
1
Trastuzumab
1
Tissue Banks
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Thoracic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled